Literature DB >> 16849400

Oligoanovulation with polycystic ovaries but not overt hyperandrogenism.

Didier Dewailly1, Sophie Catteau-Jonard, Anne-Céline Reyss, Maryse Leroy, Pascal Pigny.   

Abstract

OBJECTIVES: By requiring a minimum of two of three items [hyperandrogenism (HA), oligoanovulation (OA), and polycystic ovaries (PCO) at ultrasound], the Rotterdam definition recognizes four PCO syndrome (PCOS) phenotypes: HA+OA+PCO (full-blown syndrome), HA+OA (former National Institutes of Health definition), HA+PCO (ovulatory PCOS), and OA+PCO. However, the latter phenotype is controversial, and it is not known to what extent it shares similarities with the others.
DESIGN: The study was a comparative analysis of hormonal, metabolic, and ultrasound parameters obtained from patients and controls that were consecutively included in a database. PATIENTS AND METHODS: Sixty-six patients having OA+PCO without hirsutism or elevated serum androstenedione and testosterone levels were compared with 118 normally cycling nonhyperandrogenic age-matched women without PCO (controls). These patients (phenotype D) were also compared with patients with HA+OA+PCO (phenotype A, n = 246), HA+OA (phenotype B, n = 27), and HA+PCO (phenotype C, n = 67).
RESULTS: Patients with phenotype D had higher mean values of waist circumference and higher mean levels of serum testosterone, androstenedione, and LH than controls. Conversely, they had lower mean serum levels of FSH and SHBG (P < 0.05 for each parameter). Variance analysis disclosed significant group effects between the different patients' phenotypes for all parameters, except age, BMI, and FSH. After multiple comparisons with post hoc analysis, phenotype D had milder endocrine and metabolic abnormalities than phenotype A, although it did not differ from phenotype C, except for androgen data, by definition. Phenotypes A and B were statistically similar, except for the ultrasound data, by definition.
CONCLUSION: Oligoanovulatory patients with PCO but without HA have mild endocrine and metabolic features of PCOS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849400     DOI: 10.1210/jc.2006-1054

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

Review 1.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

2.  Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Dinka Pavičić Baldani; Lea Smirčić Duvnjak
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

Review 3.  New perspectives on the definition and management of polycystic ovary syndrome.

Authors:  R Pasquali; A Gambineri
Journal:  J Endocrinol Invest       Date:  2018-01-23       Impact factor: 4.256

Review 4.  Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?

Authors:  Susan Awdishu; Nancy I Williams; Sheila E Laredo; Mary Jane De Souza
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

5.  Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.

Authors:  Uche Ezeh; Bulent O Yildiz; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 7.  Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies.

Authors:  Marla E Lujan; Donna R Chizen; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2008-08

8.  Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance.

Authors:  V Vaggopoulos; E Trakakis; C Chrelias; P Panagopoulos; G Basios; S Makridima; V D Sioulas; G Simeonides; G Labos; E Boutati; D Kassanos
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

9.  Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).

Authors:  Susanne Tan; André Scherag; Onno Eilard Janssen; Susanne Hahn; Harald Lahner; Tiina Dietz; Susann Scherag; Harald Grallert; Carla Ivane Ganz Vogel; Rainer Kimmig; Thomas Illig; Klaus Mann; Johannes Hebebrand; Anke Hinney
Journal:  BMC Med Genet       Date:  2010-01-21       Impact factor: 2.103

10.  Antral follicle size in the downregulated cycle and its relation to in vitro fertilization outcome.

Authors:  Nabaneeta Padhy; M Latha; B Sathya; Thangam R Varma
Journal:  J Hum Reprod Sci       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.